Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 1999 • 2019 ACR/ARP Annual Meeting
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid Arthritis Through Pro-angiogenic Factor Secretion
Ha-Reum Lee¹, Su-Jin Yoo ², Chan-Geol Park ², Jinhyun Kim ², In Seol Yoo ² and Seong Wook Kang ², ¹Chungnam National University Hospital,, Daejeon, Republic of Korea, ²Chungnam National University Hospital, Daejeon, Republic of Korea
Background/Purpose: Fibroblast-like synoviocytes (FLS) are key effector cells in the pathogenesis of rheumatoid arthritis (RA) through the increased cell migration, degradation of extracellular matrix, and…
Abstract Number: 2377 • 2019 ACR/ARP Annual Meeting
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Dimitrios Pappas¹, Taylor Blachley ², Steve Zlotnick ³, Jennie Best ³, Kelechi Emeanuru ² and Joel Kremer ⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Waltham, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Methotrexate (MTX) is frequently prescribed with biologic disease-modifying antirheumatic drugs. Evidence has shown that tocilizumab (TCZ) monotherapy is effective in the treatment of patients…
Abstract Number: 495 • 2019 ACR/ARP Annual Meeting
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predicative of Developing Rheumatoid Arthritis Within 3 Years
Steven Taylor¹, Mark Parish ², LauraKay Moss ³, Marie Feser ⁴, Elizabeth Mewshaw ⁵, Jess Edison ⁵ and Kevin Deane ⁴, ¹University of Colorado - Denver, Denver, CO, ²University of Colorado Denver, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, CO, ⁴University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ⁵Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Rheumatoid arthritis (RA) related autoantibodies, in particular antibodies to citrullinated proteins (ACPA), predict likelihood of developing future RA. Indeed, clinical trials for RA prevention…
Abstract Number: 531 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Anita Kass¹, Hans Christian Gulseth ¹ and Camilla Zettel ¹, ¹Betanien Hospital, Skien, Norway
Background/Purpose: The pathogenesis of rheumatoid arthritis (RA) is unclear, and additional therapeutic approaches are needed. The improvement of RA disease activity during pregnancy, and flares during the…
Abstract Number: 985 • 2019 ACR/ARP Annual Meeting
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis
Tomohiro Koga¹, Tomohito Sato ², Yushiro Endo ¹, Sosuke Tsuji ¹, Ayuko Takatani ¹, Toshimasa Shimizu ¹, Remi Sumiyoshi ¹, Takashi Igawa ¹, Shin-ya Kawashiri ¹, Naoki Iwamoto ¹, Kunihiro Ichinose ¹, Mami Tamai ¹, Hideki Nakamura ¹, Tomoki Origuchi ³, Nobuya Yoshida ⁴, Masataka Umeda ⁵, George Tsokos ⁴ and Atsushi Kawakami ⁶, ¹Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan, ²Nagasaki University, Nagasaki, Japan, ³Nagasaki University School of health sciences, Division of physical therapy, Nagasaki, Japan, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki
Background/Purpose: Background: CD4 + T cells are important in the pathogenesis of rheumatoid arthritis (RA), and therapies targeting the differentiation of osteoclasts are attracting attention. Calcium/calmodulin-dependent…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: 2002 • 2019 ACR/ARP Annual Meeting
Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts
Samuel Finlay¹, Stefano Alivernini ², Aziza Elmesmari ³, Barbara Tolusso ², Luca Petricca ², Clara Di Mario ⁴, Annunziata Capacci ², Andrew Filer ⁵, Gianfranco Ferraccioli ², Iain McInnes ¹, Elisa Gremese ² and Mariola Kurowska-Stolarska ¹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ³Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Institute of Rheumatology - Università Cattolica del Sacro Cuore, Rome, Italy, ⁵Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Background: A substantial proportion of Rheumatoid Arthritis patients do not respond to treatment and only a small proportion achieve sustained disease remission. We showed…
Abstract Number: 2380 • 2019 ACR/ARP Annual Meeting
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Toshihisa Kojima¹, Masayo Kojima ², Hajime Ishikawa ³, Sakae Tanaka ⁴, Nobuhiko Haga ⁵, Keiichiro Nishida ⁶, Masao Yukioka ⁷, Jun Hashimoto ⁸, Hisaaki Miyahara ⁹, Yasuo Niki ¹⁰, Tomoatsu Kimura ¹¹, Hiromi Oda ¹², Shuji Asai ¹, Koji Funahashi ¹³ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Nagoya City University Graduate School of Medicne, Nagoya, Japan, ³Niigata Rheumatic Center, Niigata, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵The University of Tokyo Hospital, Tokyo, Japan, ⁶Okayama University, Graduate School of Medicine, Okayama, Japan, ⁷Yukioka Hospital, Osaka, Japan, ⁸National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ⁹National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan, ¹⁰Keio University, School of Medicine, Tokyo, Japan, ¹¹University of Toyama, Faculty of Medicine, Toyama, Japan, ¹²Department of Orthopedic Surgery, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ¹³Kariya-Toyota General Hosptal, Kariya, Japan
Background/Purpose: Total management including reconstructive joint surgery and rehabilitation should be needed for further improvements of physical function for long-standing RA patients. In these days,…
Abstract Number: 500 • 2019 ACR/ARP Annual Meeting
The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Klára Prajzlerová¹, Olga Kryštůfková ², Petra Hánová ³, Hana Hulejová ³, Monika Gregová ¹, Nora Petrovská ¹, Herman Mann ⁴, Karel Pavelka ⁴, Jiří Vencovský ⁴, Ladislav Senolt ⁴ and Mária Filková ¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic
Background/Purpose: The positivity of antibodies against citrullinated proteins (ACPA) precedes the clinical manifestation and significantly increases the risk of rheumatoid arthritis (RA). EULAR characterised individuals…
Abstract Number: 538 • 2019 ACR/ARP Annual Meeting
Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
Gerd Burmester¹, Filip Van den Bosch ², Louis Bessette ³, Alan Kivitz ⁴, Yihan Li ⁵, Alan Friedman ⁶, Aileen Pangan ⁶, Heidi Camp ⁵ and Joel Kremer ⁷, ¹Charité—University Medicine Berlin, Berlin, Germany, ²Ghent University Hospital, Ghent, Belgium, ³Laval University, Quebec City, QC, Canada, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷Albany Medical College, Albany, NY
Background/Purpose: Upadacitinib (UPA), an oral, JAK1-selective inhibitor showed efficacy over 12 weeks (wks) in patients (pts) with moderately to severely active rheumatoid arthritis (RA) and…
Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Bradley Hooker¹, Xiaomeng Zhang ², Todd Cole ², Ann Tovcimak ², Shaughn Bryant ³, Lucy Phillips ³, David Blanchard ², Dustin Wooten ², Qi Guo ², Melanie Ruzek ³, Adrian Hobson ³, Michael McPherson ³, Robert Stoffel ³, Wendy Waegell ³ and Yanping Luo ², ¹AbbVie, North Chicago, IL, ²AbbVie, North Chicago, ³AbbVie, Worcester
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…
Abstract Number: 1401 • 2019 ACR/ARP Annual Meeting
Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis
Ashley Fletcher ¹, Marissa Lassere², Lyn March ³, Catherine Hill ⁴, Claire Barrett ⁵, Graeme Carroll ⁶ and Rachelle Buchbinder ¹, ¹Cabrini Health/Monash University, Melbourne, Australia, ²St George Hospital, University of New South Wales, Sydney, Australia, ³University of Sydney, Sydney, Australia, ⁴Royal Adelaide Hospital/The University of Adelaide/The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Redcliffe Hospital, University of Queensland, Redcliffe, Australia, ⁶Fiona Stanley Hospital, Perth, Australia
Background/Purpose: To describe current biologic disease-modifying antirheumatic drug (bDMARD) treatment patterns for Australian Rheumatology Association Database (ARAD) participants with Rheumatoid Arthritis (RA) including switching and…
Abstract Number: 2004 • 2019 ACR/ARP Annual Meeting
Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis
Mikael Brink ¹, Anders Lundquist ¹, Andrey Alexeyenko ², Kristina Lejon ¹ and Solbritt Rantapää-Dahlqvist¹, ¹Umeå University, Umeå, Sweden, ²SciLife lab, Stockholm, Sweden
Background/Purpose: Antibodies and up-regulated cytokines and chemokines predate the onset of symptoms of rheumatoid arthritis (RA). The aims with this study was to identify pathways…
Abstract Number: 2381 • 2019 ACR/ARP Annual Meeting
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Clifton Bingham ⁴, Thomas Huizinga ⁵, Gustavo Citera ⁶, Kuan-Hsiang Gary Huang ⁷, Sean Connolly ⁷, Yedid Elbez ⁸, Karissa Lozenski ⁹ and Roy Fleischmann ¹⁰, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Princeton, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Phase IIIb Assessing Very Early Rheumatoid arthritis Treatment (AVERT)-2 trial (NCT02504268) is evaluating SC abatacept (ABA) + MTX versus ABA placebo (PBO) +…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].